{"id":8132,"date":"2021-12-16T12:19:53","date_gmt":"2021-12-16T17:19:53","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/vapreotide-acetate-rc-160-cas-103222-11-3-hoito-akuuttiin-ruokatorven-suonikohjuvuotoon\/"},"modified":"2021-12-16T12:19:53","modified_gmt":"2021-12-16T17:19:53","slug":"vapreotide-acetate-rc-160-cas-103222-11-3-hoito-akuuttiin-ruokatorven-suonikohjuvuotoon","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/fi\/product\/vapreotide-acetate-rc-160-cas-103222-11-3-hoito-akuuttiin-ruokatorven-suonikohjuvuotoon\/","title":{"rendered":"Vapreotide Acetate\/RC 160 CAS 103222-11-3 Hoito akuuttiin ruokatorven suonikohjuvuotoon"},"content":{"rendered":"

Vapreotide Acetate\/RC 160 CAS 103222-11-3 Hoito akuuttiin ruokatorven suonikohjuvuotoon<\/strong><\/h2>\n

Tuotteen nimi: VAPREOTIDE
\nSynonyymit: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (disulfidisilta Cys2-Cys7);HD-Phe-Cys-Tyr-D -Trp-Lys-Val-Cys-Trp-NH2; D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-CONH2 (disulfidi Cys2-Cys7); Vapreotidi, RC-160; RC-160 ;VAPREOTIDE;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2;FCYWKVCW-NH2
\nCAS: 103222-11-3
\nMF: C57H70N12O9S2
\nMW: 1131,37
\nEINECS:
\nTuoteluokat: Somatostatiinireseptori
\nMol-tiedosto: 103222-11-3.mol<\/p>\n

H3Pharma on hankkinut vaptaanin maailmanlaajuisen tutkimuskehitys- ja kaupallisen lisenssin Debiopharmilta Sveitsist\u00e4. 2001 New England Journal of Medicine raportoi v\u00e4litt\u00f6m\u00e4sti vapautuvasta formulaatiosta, jonka Chemicalbook on kliinisesti testannut ja todennut k\u00e4ytett\u00e4v\u00e4ksi varhaisessa vaiheessa akuutin ruokatorven hoidossa Vuonna 2004 Debiopharmin tyt\u00e4ryhti\u00f6, kanadalainen sy\u00f6v\u00e4n ja endokrinologian asiantuntija H3Pharma, kehitti ja valmisti uuden l\u00e4\u00e4kkeen. .<\/p>\n

Vapreotide Acetate\/ RC 160 CAS 103222-11-3 Kemialliset ominaisuudet<\/strong>
\nKiehumispiste 1540,9\u00b165,0 \u00b0C (ennustettu)
\ntiheys 1,40\u00b10,1 g\/cm3 (ennustettu)
\nvarastointi temp. \u221220\u00b0C
\npka 9,90\u00b10,15(ennustettu)<\/p>\n

Vapreotidiasetaatin\/RC 160 CAS 103222-11-3 toiminta<\/strong> ja k\u00e4ytt\u00f6
\n1. Sanvarin, somatostatiinianalogin, v\u00e4litt\u00f6m\u00e4sti vapautuva formulaatio , k\u00e4ytet\u00e4\u00e4n akuutin ruokatorven suonikohjujen verenvuodon (EVB) hoitoon.
\n2.Sanvaria k\u00e4ytet\u00e4\u00e4n ennen endoskooppista toimenpidett\u00e4 verenvuodon hallintaan ja verenvuodon uusiutumisen est\u00e4miseen kriittisten viiden p\u00e4iv\u00e4n aikana verenvuodon alkamisesta. EVB on hengenvaarallinen tila, ja kuolleisuus on korkea (noin 15\u201325 %) ensimm\u00e4isten kuuden viikon aikana verenvuodon j\u00e4lkeen. EVB aiheuttaa noin 70 % maha-suolikanavan verenvuodosta maksakirroosista k\u00e4rsivill\u00e4 potilailla.
\n3.Sanvar (vapreotidiasetaatti) on luonnossa esiintyv\u00e4n somatostatiinihormonin synteettinen oktapeptidianalogi. Sill\u00e4 on samanlaiset farmakologiset ominaisuudet kuin luonnollisella somatostatiinilla, mutta sen vaikutusaika on pidempi. Se on ainoa somatostatiinianalogi, joka on osoittanut tilastollisesti merkitt\u00e4vi\u00e4 etuja EVB:n varhaisessa hoidossa endoskooppisen hoidon yhteydess\u00e4 lumekontrolloidussa kliinisess\u00e4 tutkimuksessa (Cal\u00e8s et al. New England Journal of Medicine, 2001). Verenvuodon hallinta ja eloonj\u00e4\u00e4minen viiden p\u00e4iv\u00e4n kohdalla saavutettiin useammin Sanvarilla (p=0,021) kuin lumel\u00e4\u00e4kkeell\u00e4. Lis\u00e4tiedot<\/p>\n","protected":false},"excerpt":{"rendered":"

Tuotteen nimi: VAPREOTIDE
\nCAS: 103222-11-3
\nMF: C57H70N12O9S2
\nMW: 1131.37
\nMol Tiedosto: 103222-11-3.mol<\/p>\n","protected":false},"featured_media":2121,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[532],"product_tag":[1528],"class_list":{"0":"post-8132","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-muut-peptidit","7":"product_tag-vapreotide-acetate-rc-160-cas-103222-11-3-treatment-for-acute-esophageal-variceal-bleeding-fi","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product\/8132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/comments?post=8132"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/media\/2121"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/media?parent=8132"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_brand?post=8132"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_cat?post=8132"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_tag?post=8132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}